mbbirdy/E+ via Getty Images Stock index futures were mixed Monday as investors looked forward to another inflation report. S&P 500 futures ( SPX ) rose 0.25% to 7,419.48, and Nasdaq 100 futures ( US100:IND ) gained 0.56% to 29,227.56, while Dow futures ( INDU ) slipped 0.23% to 49,645.99. U.S. Treasury yields were little changed. The 10-year Treasury yield ( US10Y ) edged up 0.8 basis points to 4....
mbbirdy/E+ via Getty Images Stock index futures were mixed Monday as investors looked forward to another inflation report. S&P 500 futures ( SPX ) rose 0.25% to 7,419.48, and Nasdaq 100 futures ( US100:IND ) gained 0.56% to 29,227.56, while Dow futures ( INDU ) slipped 0.23% to 49,645.99. U.S. Treasury yields were little changed. The 10-year Treasury yield ( US10Y ) edged up 0.8 basis points to 4.47%, while the 2-year Treasury yield ( US2Y ) dipped 0.6 basis points to 3.99%. The 30-year Treasury yield ( US30Y ) fell 0.3 basis points to 5.03%. PPI-Final Demand will be reported before the opening bell. The report is expected to show energy price effects with a 0.5% rise on the month and 4.8% on the year. Federal Reserve speakers on tap include Boston Fed President Susan Collins, Minneapolis Fed President Neel Kashkari, and Dallas Fed President Lorie Logan. Top gainers in premarket trading included EchoStar ( SATS ) +7.84%, Coherent ( COHR ) +6.65%, and Micron Technology ( MU ) +5.50%. Decliners included W.W. Grainger ( GWW ) -4.19%, American Electric Power ( AEP ) -3.84%, and PPG Industries ( PPG ) -3.48%. More on markets CPI Inflation Blows Past Fed Rates As Core Services, Gasoline, Electricity, And Food Spike; Fed's 'Real' Rates Are Now Negative AIER's Everyday Price Index Surges, Signaling Renewed Inflation Pressure Chip Stocks FOMO Rally: Why This Could Signal The Final Blow-Off Top For The Bull Market At a glance: stocks gapping up premarket
博威合金公告，全资子公司BOVIET SOLAR CELL TECHNOLOGY (NORTH CAROLINA) LLC及BOVIET USA PROPERTY LLC拟向INOX SOLAR AMERICAS, LLC出售电池资产，电池公司拥有的太阳能电池片项目相关的所有设备以及房产公司拥有的厂房及相关设施等按协议约定的相关资产，合称电池资产。本次电池资产的总收购价款金额等于基准收购价款加上最...
博威合金公告，全资子公司BOVIET SOLAR CELL TECHNOLOGY (NORTH CAROLINA) LLC及BOVIET USA PROPERTY LLC拟向INOX SOLAR AMERICAS, LLC出售电池资产，电池公司拥有的太阳能电池片项目相关的所有设备以及房产公司拥有的厂房及相关设施等按协议约定的相关资产，合称电池资产。本次电池资产的总收购价款金额等于基准收购价款加上最终交割存货及人工费用，加上履约付款金额（如有），减去最终交割负债，其中，基准收购价款为4.13亿美元，履约付款金额基准为5700万美元。
jfmdesign/iStock Unreleased via Getty Images Hormel Foods: The Best House In A Rough Neighborhood Introduction The frozen and packaged foods industry has been under pressure for several years now, facing weak volumes and sluggish organic growth. Consumers are increasingly price sensitive against a sticky inflation backdrop, and private label pressure is rising. Many staple names are now showing fl...
jfmdesign/iStock Unreleased via Getty Images Hormel Foods: The Best House In A Rough Neighborhood Introduction The frozen and packaged foods industry has been under pressure for several years now, facing weak volumes and sluggish organic growth. Consumers are increasingly price sensitive against a sticky inflation backdrop, and private label pressure is rising. Many staple names are now showing flat or even negative revenue, but one name appears to be better positioned in this tough crowd: Hormel Foods Corporation ( HRL ) is down 30% over the past year, but it’s showing signs of stabilization. The company is also simplifying its portfolio through the divestiture of its volatile whole-bird turkey business, allowing management to focus more on higher-margin value-added protein categories. The Packaged Food Sector Is Still Struggling A quick look at the Seeking Alpha peer table reveals that weakness in the industry is not isolated to one player. The Kraft Heinz Company ( KHC ), Conagra Brands, Inc. ( CAG ), and The Campbell's Company ( CPB ) are all showing either flat or negative revenue growth year-over-year. The exception here is Hormel, which, according to the table, showed revenue growth of nearly 2%. This is unlikely to excite investors, but it’s clearly the best of a rough bunch based on this metric. Earnings are also weak across the sector, and while the industry as a whole looks inexpensive on earnings-based metrics, these low multiples are assigned for a reason. Consumers are increasingly trading down for cheaper alternatives, and private labels are seeing volumes increase after several inflation shocks. Moreover, the GLP-1 narrative is weighing on the broader packaged foods sector. As such, the issue is no longer valuation alone. Investors increasingly want to see evidence that packaged food companies can stabilize volumes without relying entirely on pricing. Hormel Is Beginning To Stabilize Recent earnings reports have shown signs of stabilization. The comp...
U.S. stock futures were mixed on Wednesday after Monday’s mostly lower close. Dow Jones futures fell, whereas S&P 500 and Nasdaq 100 indices were rising. This follows President Donald Trump‘s visit to China along with Nvidia Corp. (NASDAQ:NVDA) CEO Jensen Huang, Tesla Inc.‘s (NASDAQ:TSLA) Elon Musk, Apple Inc.’s (NASDAQ:AAPL) Tim Cook, BlackRock Inc.‘s (NYSE:BLK) Larry Fink, and Qualcomm Inc.‘s (N...
U.S. stock futures were mixed on Wednesday after Monday’s mostly lower close. Dow Jones futures fell, whereas S&P 500 and Nasdaq 100 indices were rising. This follows President Donald Trump‘s visit to China along with Nvidia Corp. (NASDAQ:NVDA) CEO Jensen Huang, Tesla Inc.‘s (NASDAQ:TSLA) Elon Musk, Apple Inc.’s (NASDAQ:AAPL) Tim Cook, BlackRock Inc.‘s (NYSE:BLK) Larry Fink, and Qualcomm Inc.‘s (NASDAQ:QCOM) Cristiano Amon. Before leaving, Trump said on Tuesday that Americans' financial struggle
BlackJack3D/E+ via Getty Images Arbutus Biopharma ( ABUS ) is a biotech company primarily focused on chronic hepatitis B, also known as HBV. The company has completed phase 1 trials and multiple Phase 2a combination studies and is in the process of preparing for Phase 2b trials. The company is targeting a very large addressable market for its primary candidate, and, if successful, this could be on...
BlackJack3D/E+ via Getty Images Arbutus Biopharma ( ABUS ) is a biotech company primarily focused on chronic hepatitis B, also known as HBV. The company has completed phase 1 trials and multiple Phase 2a combination studies and is in the process of preparing for Phase 2b trials. The company is targeting a very large addressable market for its primary candidate, and, if successful, this could be one of the best long-term stories in all of biotech. Today, however, the impetus to get involved seems low, and without more clarity on the timing of Phase 2b trials, the probability of success, or what commercialization could look like, value remains very subjective. I am on the sidelines, for now. Business Profile Arbutus is a clinical-stage biopharma company that is focused on various infectious diseases. The company's current pipeline has two therapies - Imdusiran and AB-101. Imdusiran is for HBV and is the furthest along within the pipeline, while AB-101, which is a PD-L1 inhibitor, remains in Phase 1 trials. The company was previously known as Tekmira, which spun out of Inex Pharmaceuticals in 2007. To set the stage on HBV therapy, approximately 254 million people are living with cHBV (chronic HBV), and 1.2 million new infections are added each year. This is a rather large total addressable market, seen below. The population pool is largely centered in Africa and Asia. There are two types of HBV - acute and chronic. Acute can sometimes go away on its own, but chronic, as the name suggests, persists with the patient. The issue with cHBV is that it can cause cirrhosis of the liver, which is essentially scarring that can lead to liver failure. In other cases, it can cause liver cancer, making this particularly deadly. This disease has led to millions of deaths. The WHO report from last year showed that in 2022, 1.1 million people died from complications from cHBV. Investor Presentation Investors should note that the company has been involved in patent litigation against Pf...
Nike (NYSE: NKE) stock has been going through an extended rough patch. Sales and earnings have been under pressure, and industry dynamics have also called into question the extent of the company's brand strength. In addition to softer demand in key geographic markets, the company has also seen its profit margins eroded. The company posted a net income margin of just 4.6% in the third quarter of it...
Nike (NYSE: NKE) stock has been going through an extended rough patch. Sales and earnings have been under pressure, and industry dynamics have also called into question the extent of the company's brand strength. In addition to softer demand in key geographic markets, the company has also seen its profit margins eroded. The company posted a net income margin of just 4.6% in the third quarter of its current fiscal year -- which ended Feb. 28. For comparison, the business had recorded a net income margin of 7% in last year's quarter. For another point of comparison, the business posted a net income margin of roughly 9.7% in fiscal Q3 of 2024. Revenue was up just 0.3% year over year in fiscal Q3. Image source: Getty Images. Continue reading
Birkenstock Holding press release ( BIRK ): Q2 Adjusted net profit of EUR 93 million, down 10% and Adjusted EPS of EUR 0.50, Revenue of EUR 618 million, an increase of 8% on a reported basis and 14% in constant currency B2B revenue growth of 9% (15% in constant currency) and DTC revenue growth of 4% (12% in constant currency) Gross profit margin of 53.9%, down 380 basis points from 57.7% in the pr...
Birkenstock Holding press release ( BIRK ): Q2 Adjusted net profit of EUR 93 million, down 10% and Adjusted EPS of EUR 0.50, Revenue of EUR 618 million, an increase of 8% on a reported basis and 14% in constant currency B2B revenue growth of 9% (15% in constant currency) and DTC revenue growth of 4% (12% in constant currency) Gross profit margin of 53.9%, down 380 basis points from 57.7% in the prior-year period primarily due to unfavorable currency translation (230 basis points), incremental U.S. tariffs (90 basis points) and channel mix (30 basis points) The Company is confirming its guidance for Fiscal 2026: 13-15% revenue growth in constant currency Adjusted gross profit margin of 57.0-57.5% Adjusted EBITDA margin of 30.0-30.5% Tax rate of 26-28% Adjusted EPS of EUR 1.90-2.05, inclusive of tariff and F/X impacts Capital expenditures in range of EUR 110-130 million. More on Birkenstock Holding Birkenstock: Tough To Get Excited Birkenstock: Still A Long-Term Hold, But Not A Perfect Story (Downgrade) Birkenstock Holding plc 2026 Q1 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Birkenstock Holding Historical earnings data for Birkenstock Holding
Alibaba Group Holding Ltd. reported weaker-than-expected sales, stoking concerns about its ability to convert substantial AI investments into a major growth driver. Revenue rose 3% to 243.4 billion yuan ($35.8 billion), while analysts on average looked for 246.5 billion yuan. Net income roughly doubled to 25.5 billion yuan, thanks in part to equity investment gains. The Hangzhou-based company rais...
Alibaba Group Holding Ltd. reported weaker-than-expected sales, stoking concerns about its ability to convert substantial AI investments into a major growth driver. Revenue rose 3% to 243.4 billion yuan ($35.8 billion), while analysts on average looked for 246.5 billion yuan. Net income roughly doubled to 25.5 billion yuan, thanks in part to equity investment gains. The Hangzhou-based company raised prices for its AI and cloud services, pivoted to focus on proprietary models and restructured its teams this year to better profit from its AI capabilities. Chief Executive Officer Eddie Wu has said the company aims to quintuple cloud and AI revenue to $100 billion annually in five years. But its performance has been affected by competition with Meituan and JD.com Inc. over the past year. Like their US peers, China’s top AI players including Alibaba are facing increasing pressure from investors to translate their AI expenditure into lucrative returns. Among major Chinese tech firms, Alibaba is one of the biggest spenders with a pledge to shell out some $53 billion on AI over a three-year span, while its cloud service unit has become its fastest-growing business. Read: Alibaba, Tencent AI Bets Face ‘Show Me the Profits’ Scrutiny As part of the Hangzhou company’s AI commercialization efforts, Wu helped set up and lead a new business group — Alibaba Token Hub — to streamline operations by bringing most research functions as well as consumer and enterprise products under one umbrella, a move that has earned positive reactions. “We expect Alicloud growth momentum to remain intact, supported by a robust surge in token usage,” Morgan Stanley analysts led by Gary Yu said in a pre-earnings note. What Bloomberg Intelligence Says Alibaba is likely to lean even harder into AI integration across its ecosystem in fiscal 2027, keeping expenditure high to spur user adoption. That will cap how much its China e-commerce margins can rebound, even as its quick-commerce spending becomes more...